



doi: 10.2169/internalmedicine.3214-19 Intern Med 58: 3603-3604, 2019 http://internmed.jp

## [ PICTURES IN CLINICAL MEDICINE ]

## Papulopustular Rash Due to Tocilizumab

Junko Kohro-Kawata<sup>1</sup> and Mitsuyo Kinjo<sup>2</sup>

Key words: papulopustular rash, tocilizumab

(Intern Med 58: 3603-3604, 2019) (DOI: 10.2169/internalmedicine.3214-19)



Picture 1.



Picture 2.

A 43-year-old woman with systemic sclerosis developed generalized pruritic erythematous papules. Systemic sclerosis was diagnosed based on a fever, arthritis, and sclerodactyly with positive findings for anti-nuclear antibody 1280x (discrete pattern) and anti-centromere antibody. While the arthritis improved, painful pruritic papules with pustular elements appeared on both arms and buttocks (Picture 1), and some bruising was noted over the thighs (Picture 2) after 5 doses of subcutaneously injected tocilizumab (162 mg every 2 weeks). The rash failed to respond to a topical steroid and

antifungal ointment but promptly improved after the discontinuation of tocilizumab. Tocilizumab is a humanized antihuman interleukin-6 (IL-6) receptor monoclonal antibody. Cutaneous reactions to tocilizumab have included psoriasiform rash and leukocytoclastic vascultis (1). The paradoxical increase in circulating IL-6 after the inhibition of the IL-6 receptor by tocilizumab may result in the intraepidermal recruitment of neutrophils and keratinocyte hypertrophy, which is seen in cases of psoriasiform rash and other forms of skin reactions (2).

## The authors state that they have no Conflict of Interest (COI).

## References

- Palmou-Fontana N, Sanchez Gavino JA, McGonagle D, Garcia-Martinez E, Iniguez de Onzono Martin L. Tocilizumabinduced psoriasiform rash in rheumatoid arthritis. Dermatology 228: 311-313, 2014.
- Saggini A, Chimenti S, Chiricozzi A. IL-6 as a druggable target in psoriasis: focus on pustular variants. J Immunol Res 2014: 964069,

<sup>1</sup>Kawata-Junko Clinic, Japan and <sup>2</sup>Division of Rheumatology, Okinawa Chubu Hospital, Japan Received: April 18, 2019; Accepted: July 1, 2019; Advance Publication by J-STAGE: August 28, 2019 Correspondence to Dr. Junko Kawata, junko@jk-clinic.jp 2014.

The Internal Medicine is an Open Access journal distributed under the Creative

Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/ by-nc-nd/4.0/).

© 2019 The Japanese Society of Internal Medicine Intern Med 58: 3603-3604, 2019